Simu K. Thomas

1.9k total citations
56 papers, 1.5k citations indexed

About

Simu K. Thomas is a scholar working on Pediatrics, Perinatology and Child Health, Psychiatry and Mental health and Genetics. According to data from OpenAlex, Simu K. Thomas has authored 56 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pediatrics, Perinatology and Child Health, 14 papers in Psychiatry and Mental health and 13 papers in Genetics. Recurrent topics in Simu K. Thomas's work include Health Systems, Economic Evaluations, Quality of Life (10 papers), Dementia and Cognitive Impairment Research (10 papers) and Hemoglobinopathies and Related Disorders (10 papers). Simu K. Thomas is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (10 papers), Dementia and Cognitive Impairment Research (10 papers) and Hemoglobinopathies and Related Disorders (10 papers). Simu K. Thomas collaborates with scholars based in United States, United Kingdom and Switzerland. Simu K. Thomas's co-authors include Jean‐François Baladi, Thomas E. Delea, Oleg Sofrygin, Pradyumna D. Phatak, Thomas D. Coates, Roger Lane, Jörge E. Cortes, Henry J. Henk, Alan K. Hatfield and Theodore Darkow and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Simu K. Thomas

54 papers receiving 1.4k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Simu K. Thomas 405 401 305 204 190 56 1.5k
Désirée van der Heijde 215 0.5× 678 1.7× 273 0.9× 118 0.6× 101 0.5× 57 3.5k
Marie‐Hélène Lafeuille 111 0.3× 123 0.3× 714 2.3× 220 1.1× 117 0.6× 148 2.0k
Lin Xie 116 0.3× 119 0.3× 198 0.6× 170 0.8× 69 0.4× 88 1.4k
K. Jack Ishak 118 0.3× 121 0.3× 225 0.7× 438 2.1× 507 2.7× 43 2.0k
Shravanthi R. Gandra 119 0.3× 293 0.7× 108 0.4× 446 2.2× 50 0.3× 61 2.1k
Michael Eaddy 59 0.1× 114 0.3× 307 1.0× 257 1.3× 203 1.1× 96 1.5k
Irina Proskorovsky 122 0.3× 239 0.6× 248 0.8× 178 0.9× 255 1.3× 65 1.2k
Aurore Palmaro 77 0.2× 334 0.8× 124 0.4× 97 0.5× 56 0.3× 42 1.2k
Safiya Abouzaid 82 0.2× 405 1.0× 92 0.3× 164 0.8× 250 1.3× 41 971
Catherine Copley‐Merriman 93 0.2× 87 0.2× 70 0.2× 469 2.3× 202 1.1× 68 1.7k

Countries citing papers authored by Simu K. Thomas

Since Specialization
Citations

This map shows the geographic impact of Simu K. Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simu K. Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simu K. Thomas more than expected).

Fields of papers citing papers by Simu K. Thomas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simu K. Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simu K. Thomas. The network helps show where Simu K. Thomas may publish in the future.

Co-authorship network of co-authors of Simu K. Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Simu K. Thomas. A scholar is included among the top collaborators of Simu K. Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simu K. Thomas. Simu K. Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Buessing, Marric, et al.. (2020). Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria. PharmacoEconomics. 38(9). 981–994. 18 indexed citations
2.
3.
Buessing, Marric, et al.. (2019). PRO33 COST–UTILITY ANALYSIS OF RAVULIZUMAB COMPARED WITH ECULIZUMAB IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA. Value in Health. 22. S341–S341. 1 indexed citations
4.
Jain, Minal, et al.. (2014). The Economic Impact Of Cardiovascular Events In Patients Post Myocardial Infarction: Uk Health Care Perspective. Value in Health. 17(7). A483–A484. 2 indexed citations
5.
Lin, Feng, et al.. (2014). Long-Term Costs and Consequences of Patients with Familial Chylomicronemia Syndrome – A Simulation Model Approach. Value in Health. 17(7). A400–A400. 4 indexed citations
6.
Bhattacharyya, S., et al.. (2014). A De-Novo Economic Model to Assess Clinical and Economic Consequences of Bronchiectasis. Value in Health. 17(7). A551–A551.
7.
Lin, Feng, Simu K. Thomas, & Michael Baldwin. (2013). Microsimulation or Cohort Modelling? A Case Study in Chronic Obstructive Pulmonary Disease (COPD). Value in Health. 16(7). A586–A586. 1 indexed citations
8.
Mitchell, Paul, Lieven Annemans, Richard G. White, Meghan Gallagher, & Simu K. Thomas. (2011). Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration. PharmacoEconomics. 29(2). 107–131. 43 indexed citations
9.
Nagy, Balàzs, et al.. (2010). Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models. International Journal of Geriatric Psychiatry. 26(5). 483–494. 15 indexed citations
10.
Winblad, Bengt, Ariane K. Kawata, Kathleen Beusterien, et al.. (2007). Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. International Journal of Geriatric Psychiatry. 22(5). 485–491. 86 indexed citations
11.
12.
Delea, Thomas E., Oleg Sofrygin, Simu K. Thomas, et al.. (2007). Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients. PharmacoEconomics. 25(4). 329–342. 70 indexed citations
13.
Hatoum, Hind T., Swu‐Jane Lin, Stephen Arcona, et al.. (2005). The Use of the Occupational Disruptiveness Scale of the Neuropsychiatric Inventory-Nursing Home Version to Measure the Impact of Rivastigmine on the Disruptive Behavior of Nursing Home Residents With Alzheimer’s Disease. Journal of the American Medical Directors Association. 6(4). 238–245. 13 indexed citations
14.
Narayanan, S, et al.. (2005). Antipsychotic Drug Use Among Nursing Home Residents Taking Rivastigmine. Journal of the American Medical Directors Association. 7(1). 12–16. 14 indexed citations
15.
Lee, Won Chan, Steve Arcona, Simu K. Thomas, et al.. (2005). Effect of comorbidities on medical care use and cost among refractory patients with partial seizure disorder. Epilepsy & Behavior. 7(1). 123–126. 36 indexed citations
16.
Suh, Dong‐Churl, Simu K. Thomas, Elmira Valiyeva, Stephen Arcona, & Lien Vo. (2005). Drug Persistency of Two Cholinesterase Inhibitors. Drugs & Aging. 22(8). 695–707. 44 indexed citations
17.
Hughes, Anthony J., et al.. (2004). Gastrointestinal Adverse Events in a General Population Sample of Nursing Home Residents Taking Cholinesterase Inhibitors. The Consultant Pharmacist. 19(8). 713–720. 7 indexed citations
18.
Suh, Dong‐Churl, Stephen Arcona, Simu K. Thomas, et al.. (2004). Risk of Antipsychotic Drug Use in Patients with Alzheimer???s Disease Treated with Rivastigmine. Drugs & Aging. 21(6). 395–403. 22 indexed citations
19.
Brooks, Sandra E., et al.. (2002). Association of Knowledge, Anxiety, and Fear with Adherence to Follow Up for Colposcopy. Journal of Lower Genital Tract Disease. 6(1). 17–22. 31 indexed citations
20.
Hamroff, Glenn S., Stephen A. Katz, Rachel Bijou, et al.. (1998). Clinical benefits of long-term angiotensin II receptor blockade in patients with severe symptoms of congestive heart failure despite full angiotensin converting enzyme inhibition. Journal of the American College of Cardiology. 31. 188–188. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Désirée van der Heijde Breakdown of academic impact, for papers by Marie‐Hélène Lafeuille Breakdown of academic impact, for papers by Lin Xie Breakdown of academic impact, for papers by K. Jack Ishak Breakdown of academic impact, for papers by Shravanthi R. Gandra Breakdown of academic impact, for papers by Michael Eaddy Breakdown of academic impact, for papers by Irina Proskorovsky Breakdown of academic impact, for papers by Aurore Palmaro Breakdown of academic impact, for papers by Safiya Abouzaid Breakdown of academic impact, for papers by Catherine Copley‐Merriman
Rankless by CCL
2026